Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
The CYBN news page on Stock Titan provides an archive of news releases and updates related to Cybin Inc., a Phase 3 clinical-stage neuropsychiatry and pharmaceutical company focused on developing next-generation treatment options for mental health conditions. These news items come directly from the company’s public communications and are also referenced in its Form 6-K filings with the U.S. Securities and Exchange Commission.
Readers can find coverage of Cybin’s clinical development programs, including updates on its lead candidates CYB003, a proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder, and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. News releases describe milestones such as trial enrollment progress, regulatory approvals to initiate studies in various countries, and participation in healthcare and investor conferences.
The news feed also includes information on Cybin’s capital markets activity, such as registered direct offerings of common shares and pre-funded warrants, the establishment and use of an at-the-market equity program, and the company’s stated intentions for the use of proceeds, including repayment of convertible debentures and funding of its clinical programs. Corporate updates, including plans to transfer its U.S. stock exchange listing from the NYSE American to the Nasdaq Global Market and the associated change in ticker symbol from CYBN to HELP, are documented in detail.
Because Cybin files many of these news releases as exhibits to Form 6-K, the CYBN news page serves as a convenient way to follow the narrative of its clinical progress, financing decisions, and listing changes over time. Investors and researchers can use this archive to review how the company describes its strategy in neuropsychiatry, its geographic operations in Canada, the United States, the United Kingdom, and Ireland, and its stated commitment to rigorous scientific research and regulatory compliance for its investigational compounds.
Cybin, a biopharmaceutical company focused on advancing Psychedelics to Therapeutics, announced that CEO Doug Drysdale will present at the Jefferies London Healthcare Conference from November 18-19, 2021. The presentation will be available on demand starting November 18 at 8:00 AM GMT until November 19 at 5:00 PM GMT. Investors can access the webcast through Cybin's website. Founded in 2019 and headquartered in Canada, Cybin collaborates with leading partners to develop therapeutics for mental health issues.
Cybin Inc. (NYSE American:CYBN) will report its financial results for Q2 fiscal 2021, ending September 30, 2021, on November 15, 2021. A conference call to discuss results will occur on the same day at 4:30 p.m. EST, hosted by CEO Doug Drysdale. The company is dedicated to developing safe and effective psychedelic therapeutics for mental health. Cybin operates in Canada, the U.S., the UK, and Ireland, leveraging advanced drug discovery and delivery systems.
Cybin Inc. (AMEX:CYBN) has been granted a Schedule I manufacturing license by the U.S. Drug Enforcement Agency (DEA) for its Boston area research lab. This license allows the company to enhance its internal research and development capabilities for studying Schedule I controlled substances, marking a significant progression in their clinical and regulatory efforts. Additionally, Leah Gibson has been appointed as the new Vice President of Investor Relations, bringing over 18 years of experience in the life sciences sector. Former Chief Business Officer John Kanakis will transition to focus on M&A and business development.
Cybin Inc. (AMEX:CYBN) announces a research and development briefing scheduled for November 8, 2021, from 8:30 AM to 9:30 AM EST in Miami. The event will unveil positive pre-clinical research findings regarding the psilocybin molecule as a potential therapeutic for mental health issues. Cybin emphasizes its commitment to creating effective and safe treatment options amidst a growing mental health crisis exacerbated by COVID-19. The briefing will feature key insights from the company’s leadership and include a Q&A session for attendees.
Cybin Inc. (AMEX:CYBN) has launched the EMBARK Psychedelic Facilitator Training Program aimed at preparing clinical trial facilitators to ethically support participants receiving psychedelic treatment. The program, in collaboration with the University of Washington, includes an in-person training retreat and is set to kick off this fall. The initial cohort will prepare for a clinical trial investigating psilocybin-assisted psychotherapy for healthcare workers facing COVID-related distress. EMBARK employs a transdiagnostic model to address various therapeutic needs, emphasizing a holistic approach to healing.
Cybin has received FDA authorization for an Investigational New Drug (IND) application to conduct a feasibility study measuring ketamine's psychedelic effects using Kernel’s Flow technology. This innovative neuroimaging technology allows for the dynamic tracing of brain activity during psychedelic experiences, representing a significant advancement in psychedelic therapeutics. The study aims to gather real-time quantitative data, potentially enhancing the understanding of psychedelic treatments for psychiatric disorders. Cybin retains exclusive rights to any innovations derived from the study.
Cybin Inc. has completed its 74th pre-clinical study to advance its psychedelic compounds, CYB003 and CYB004, toward clinical development. Over 50 novel compounds have been evaluated, showcasing advantages like faster onset, shorter duration, and excellent bioavailability. Safety studies adhering to FDA standards have commenced, with human studies expected in early 2022. The company aims to establish a strong portfolio of psychedelic molecules for potential therapeutic applications in mental health.
Cybin Inc. (AMEX:CYBN) has filed an international patent application under the Patent Cooperation Treaty (PCT) for innovative methods of delivering psychedelic medications through inhalation. The application aims to secure patent coverage across 153 countries, enhancing the Company's intellectual property portfolio. This approach may optimize session timing, reduce drug dosages while maintaining efficacy, and provide better control during sessions. The filing is part of Cybin's ongoing development program for its proprietary psychedelic molecule, CYB004.
Cybin Inc. announces milestones achieved by its subsidiary, Adelia Therapeutics Inc., under a December 2020 contribution agreement. Adelia has met certain Year 2 Q1 milestones, leading to the issuance of $706,586.69 in Class B shares to Adelia shareholders. These shares can be exchanged for Cybin common shares at a 10 to 1 ratio starting December 2021, with phased exchange limits until December 2023. The firm focuses on advancing psychedelic therapies, aiming to enhance dosing efficacy and address unmet medical needs.
Cybin Inc. announced key management changes and engagement with ROK Consulting to enhance market communications. Dr. Amir Inamdar joined as Chief Medical Officer for European Operations, and Dr. Geoff Varty became Head of Research & Development. Lori Challenger was promoted to Chief Compliance, Ethics & Administrative Officer, while Robert Mino was named General Counsel. The engagement with ROK includes a three-month contract at $500,000 per month, plus options for shares at CDN$2.78. This aims to improve the company's engagement with financial markets.